Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Cholestatic Pruritus Market Grown from 2024 to 2025?
The market size for cholestatic pruritus has experienced significant growth in the past few years. The market is forecasted to further expand, rising from $19.20 billion in 2024 to $20.28 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 5.6%. The positive performance in the historical period can be associated with increasing incidences of skin conditions, escalated investment in R&D, the need for efficient treatments, growing disease awareness and supportive regulatory landscapes.
What Growth Rate Is Anticipated for the Cholestatic Pruritus Market in the Coming Years?
Significant expansion is anticipated for the cholestatic pruritus market in the coming years, with projections indicating a growth to $24.97 billion by 2029, a surge propelled by a compound annual growth rate (CAGR) of 5.3%. Contributing factors to this positive trend during the forecast period are an increasing elderly population, a rise in cases of atopic dermatitis and urticaria, a larger aging population, a proliferation in chronic kidney disease cases and a growing number of conditions related to pruritus. Key developments for this period would incorporate new treatment alternatives, collaborations with major companies focusing on cholestatic pruritus research, advancements in treatment methodologies, healthcare facility expansion and technological innovation.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21140&type=smp
Who Are the Leading Companies in the Cholestatic Pruritus Market?
Major companies operating in the cholestatic pruritus market are GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Merck KGaA, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Incyte Corporation, Ipsen Pharma, Vanda Pharmaceuticals Inc., Medison Pharma Ltd., Mirum Pharmaceuticals Inc., Albireo Pharma Inc., Dipharma Francis S.r.l., Cara Therapeutics Inc., CANbridge Pharmaceuticals Inc., Escient Pharmaceuticals Inc., Tharimmune Inc., Vifor Fresenius Medical Care Renal Pharma, CymaBay Therapeutics Inc., ICE Pharma Inc., Aquatic Remedies Private Limited.
What Are the Key Drivers of the Cholestatic Pruritus Market?
The progression of the cholestatic pruritus market is expected to be fueled by the escalating incidence of liver diseases. A variety of conditions that impair liver function, such as infections, autoimmune disorders, genetic ailments, and damage from toxins, all fall under liver diseases, often resulting in inflammation, scarring, or liver failure. The rising occurrence of liver diseases is spurred by factors like obesity, diabetes, alcohol consumption, viral hepatitis infections, and exposure to environmental toxins. Cholestatic pruritus plays a crucial role in the detection and management of liver diseases, acting as a significant symptom signifying a malfunction in bile flow, frequently hinting at the need for further examination and treatment of underlying liver conditions. For example, as per the Office for Health Improvement and Disparities, a UK government entity focusing on health inequality issues, hospital admissions for liver disease in England saw a 22% increase in the year ending 2022, ascending from 67,458 to 82,290. Hence, the rising incidence of liver diseases is anticipated to propel the growth of the cholestatic pruritus market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21140&type=smp
What Are the Key Market Segments in the Cholestatic Pruritus Industry?
The cholestatic pruritus market covered in this report is segmented –
1) By Disease Type: Primary Biliary Cholangitis (PBC), Primary Sclerosing Cholangitis (PSC), Intrahepatic Cholestasis of Pregnancy (ICP), Other Disease Types
2) By Treatment Type: Medications, Phototherapy, Other Treatment Types
3) By Route Of Administration: Oral, Topical, Injectable
4) By End-User: Hospitals, Clinics, Ambulatory Care Centers, Homecare
Subsegments:
1) By Primary Biliary Cholangitis (PBC): Early-Stage PBC, Advanced PBC, PBC With Cirrhosis, PBC With Liver Failure
2) By Primary Sclerosing Cholangitis (PSC): Classic PSC, PSC With Ulcerative Colitis, PSC With Bile Duct Strictures
3) By Intrahepatic Cholestasis of Pregnancy (ICP): Mild ICP, Severe ICP, ICP With Preterm Birth Risk
4) By Other Disease Types: Alcoholic Cholestasis, Drug-Induced Cholestasis, Viral Hepatitis-Induced Cholestasis, Genetic Cholestasis Disorders
What Are the Latest Trends in the Cholestatic Pruritus Market?
Leading businesses in the cholestatic pruritus sector are concentrating on the development of cutting-edge solutions like oral solutions for more efficacious management of symptoms, enhancing patient adherence, and delivering specialised relief by resolving the root causes of bile salt build-up and inflammation. A liquid medication intended to lessen bile acid accumulation and soothe severe itchiness in cholestasis patients describes an oral remedy for cholestatic pruritus. For example, Mirum Pharmaceuticals Inc., a biopharmaceutical firm based in the US, was conferred approval from the U.S. Food and Drug Administration (FDA) in March 2024 for LIVMARLI (maralixibat) oral solution to treat cholestatic pruritus in patients who are at least five years old and are suffering from progressive familial intrahepatic cholestasis (PFIC). This inhibitor of ileal bile acid transporter, administered orally once a day, is identified as a groundbreaking therapy for PFIC type 2. LIVMARLI is projected to profoundly affect those patients with cholestatic pruritus associated with PFIC, presenting a desperately required treatment alternative for those with the rarest subtypes.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/cholestatic-pruritus-global-market-report
What Are the Key Regional Markets in the Cholestatic Pruritus Industry?
North America was the largest region in the cholestatic pruritus market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cholestatic pruritus market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21140
This Report Delivers Insight On:
1. How big is the cholestatic pruritus market, and how is it changing globally?
2. Who are the major companies in the cholestatic pruritus market, and how are they performing?
3. What are the key opportunities and risks in the cholestatic pruritus market right now?
4. Which products or customer segments are growing the most in the cholestatic pruritus market?
5. What factors are helping or slowing down the growth of the cholestatic pruritus market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model